Common Shares, Without Par Value
- Symbol
- ABT
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
ABTNYSEEQUITYCurrent
Item 8.01 Other Events. As previously disclosed in Abbott’s Annual Reports on Form 10-K for the fiscal years ended December 31, 2024 and December 31, 2025, six shareholder derivative lawsuits have been pending in a consolidated proceeding, In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation, before the United States District Court for the Northern District of Illinois agains…
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X, and YouTube.
ABBOTT LABORATORIES · 8-K · Filed 2026-04-17
EX-99.1 2 tm2611915d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION -------------------------------------------------------x IN RE ABBOTT LABORATORIES INFANT FORMULA SHAREHOLDER DERIVATIVE LITIGATION CASE NO: 1:22-cv-5513 Hon. Sunil R. Harjani Hon. Laura K. McNally -------------------------------------------------------x NOTICE OF PROPOSED SETTLEMENT OF CONSOLIDATED DERIVATIVE ACTION, FINAL SETTLEMENT HEARING, AND RIGHT TO APPEAR TO: ALL CURRENT HOLDERS OF ABBOTT LABORATORIES COMMON STOCK PLEASE READ THIS NOTICE CAREFULLY THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS HAS AUTHORIZED THIS NOTICE TO BE SENT TO YOU THIS IS NOT A SOLICITATION This notice (the “Notice”) advises you of the proposed settlement (the “Settlement”) of derivative claims brought against certain current and former directors and officers (“Individual Defendants”) of Abbott Laboratories (“Abbott” or the “Company”) (collectively with the Individual Defendants, “Defendants”). The parties to the Consolidated Derivative Action (as defined below), have entered into a Stipulation and …
Open exhibit ↗